Entry Detail


General Information

Database ID:TRD02756
Confidence:High
Contents:>> tsRNA Information
>> tsRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference



tsRNA Information

tsRNA Name:3'U-tRFValCAC
tsRNA Type:tRF-3
Amino acid and Anticodon:ValCAC
Sequence:N/A
Related Target:N/A
Predicted Target:N/A
External Links:
MINTbase ID:N/A
tRFdb ID:N/A



tsRNA Association Statistics

Total Associated Disease Number:3
More Information
Network:
(Display the first 15 nodes)



Disease Information

 MeSHDisease Ontology
Disease ID:D010051DOID:2394
Disease Name:Ovarian Neoplasmsovarian cancer
Category:MeSHDisease Ontology
Type:Neoplasms//Urogenital Diseases//Endocrine System Diseasesdisease of anatomical entity//disease of cellular proliferation
Define:Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. A female reproductive organ cancer that is located_in the ovary.
Alias:Cancer of Ovary//Cancer of the Ovary//Neoplasms, Ovarian//Ovarian Cancer//Ovary Cancer//Ovary Neoplasmsmalignant Ovarian tumor//malignant tumour of ovary//ovarian neoplasm//ovary neoplasm//primary ovarian cancer//tumor of the Ovary



Disease Association Statistics

Total Associated tsRNA Number:74
More Information
Network:
(Display the first 15 nodes)



Evidence Support

Strong Evidence:RT-PCR
Weak Evidence:High-throughput sequencing



Reference

[1] PubMed ID:36599181
Disease Name:Ovarian Neoplasms
Tissue:Ovarian Cancer
Dysfunction Pattern:Up-Regulation
Validated Method:RT-PCR//High-throughput sequencing
Description:tRNA-derived small RNA 30U-tRFValCAC promotes tumour migration and early progression in ovarian cancer.
Comparision:Cancer VS Normal
Mechanism:Following primary clinical assessment, target prediction and gene ontology analyses, the 30U-tRFValCAC (derived from pre-tRNAValCAC) was highlighted to regulate cell proliferation and adhesion, and to correlate with inferior patients' outcome. 30U-tRFValCAC transfection of SK-OV-3 and OVCAR-3 cells resulted in significantly increased cell growth and migration, in a dose-dependent manner. Elevated tumour 30U-tRFValCAC levels were associated with significantly higher risk for early progression and worse survival following firstline platinum-based chemotherapy, independently of patients' clinicopathological data, chemotherapy response, and residual tumour. Interestingly, 30U-tRFValCAC-fitted multivariate models improved risk stratification and provided superior clinical net benefit in prediction of treatment outcome compared to disease established markers.